Can a new drug shrink Hard-to-Treat tumors?
NCT ID NCT05502393
First seen Aug 07, 2026 · Last updated Aug 07, 2026
Summary
This early-stage trial is testing an experimental drug called JS107 in people with advanced or metastatic solid tumors that have not responded to standard treatments. The study aims to find the safest dose and see how well the body tolerates JS107 when given alone or combined with another immunotherapy drug, toripalimab. Some participants may also receive chemotherapy drugs oxaliplatin and capecitabine as part of the combination. The goal is to determine the recommended dose for future studies and to look for early signs of tumor shrinkage.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- JS107 (an experimental drug) given alone or with toripalimab, and in some cases with oxaliplatin and capecitabine
- What this could lead to
- If JS107 proves safe and shows signs of shrinking tumors, it could become a new treatment option for advanced solid tumors that have not responded to other therapies.
- What could go wrong
- This is an early-phase trial focused on safety and dosing, so it is too soon to know if JS107 will work. Side effects may be significant, and the drug may not benefit all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Anyang Tumor Hospital
An'yang, Henan, 455100, China
-
First Affiliated Hospital of Wenzhou Medical University
Wenzhou, Zhejiang, 325000, China
-
Fujian Cancer Hospital
Fuzhou, Fujian, 350014, China
-
Gansu Wuwei Tumour Hospital
Wuwei, Gansu, 733000, China
-
Harbin Medical University Cancer Hospital
Harbin, Heilongjiang, 150081, China
-
Hubei Cancer Hospital
Wuhan, Hubei, 430079, China
-
Meizhou People's Hospital
Meizhou, Guangdong, 514000, China
-
Suining Central Hospital
Suining, Sichuan, 629000, China
-
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, 510060, China
-
The Affiliated Hospital of Qingdao University
Qingdao, Shandong, 266061, China
-
The First Affiliated Hospital of Henan University of Science and Technology
Luoyang, Henan, 471003, China
-
The First Affiliated Hospital of Henan University of Science and Technology
Hangzhou, Zhejiang, 310009, China
-
The First Affiliated Hospital of Xinxiang Medical University
Xinxiang, Henan, 453003, China
-
The First Affiliated Hospital of Zhejiang University Medical College
Hangzhou, Zhejiang, 310003, China
-
The First Hospital of China Medical University
Shenyang, Liaoning, 110000, China
-
The Fourth Hospital of Hebei Medical University
Shijiazhuang, Hebei, 50011, China
-
The People's Hospital of Chizhou
Chizhou, Anhui, 247099, China
-
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, 430010, China
-
Wuhan University People's Hospital
Wuhan, Hebei, 430060, China
-
Zhejiang Cancer Hospital
Hangzhou, Zhejiang, 310005, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can your own immune cells beat advanced cancer?
- Tumor DNA mapping may unlock personalized cancer therapies
- Can a new drug combo shrink Hard-to-Treat tumors?
- Can a pill outsmart Tumors' defenses?
- Can a new immune drug outsmart Hard-to-Treat tumors?
- Can a protein calm the immune System's overreaction to cancer treatment?